Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
5.72
+0.12 (2.14%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Akari Therapeutics, Employees
As of December 31, 2025, Akari Therapeutics, had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 3 or -33.33% compared to the previous year.
Employees
6
Change (1Y)
-3
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$2,883,000
Market Cap
6.47M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| FibroBiologics | 15 |
| BioRestorative Therapies | 14 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 10 |
| Immuron | 7 |
| Can-Fite BioPharma | 5 |
| Acurx Pharmaceuticals | 4 |
AKTX News
- 1 day ago - Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload - GlobeNewsWire
- 7 days ago - Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors - GlobeNewsWire
- 8 days ago - Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing - GlobeNewsWire
- 19 days ago - Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC - GlobeNewsWire
- 22 days ago - Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing - GlobeNewsWire
- 5 weeks ago - Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 - GlobeNewsWire
- 6 weeks ago - Akari Therapeutics Announces ADS Ratio Change - GlobeNewsWire
- 6 weeks ago - Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala - GlobeNewsWire